3. Renal Denervation Two Late-Breaking Clinical Trials

4. SYMPLICITY HTN-3 Trial Objectives

5. Key Inclusion Criteria

6. Primary Efficacy End Points

7. Unique Qualities of SYMPLICITY HTN-3

9. Global SYMPLICITY Registry (cont)

10. Change in Ambulatory SBP for Global SYMPLICITY Registry and SYMPLICITY HTN-3 Patients

11. Issues to Address Following HTN-3

12. Response Rates* for Patients With Office SBP ≥160 mm Hg/Ambulatory SBP ≥135 mm Hg at Baseline†

13. SYMPLICITY HTN-3 Myths Dispelled

14. Results Prespecified Subgroup Analyses

15. Areas to Advance

16. Global SYMPLICITY Registry Number of Ablations per Patient

17. Pleiotropic Effects of Renal Denervation

18. Key Points and Moving Forward

19. Abbreviations

20. References